Connect
MJA
MJA

Successful implementation of cardiometabolic monitoring of patients treated with antipsychotics

Debra L Foley, Katherine I Morley, Karyn E Carroll, John Moran, Patrick D McGorry and Brendan P Murphy
Med J Aust 2009; 191 (9): 516-518.
Published online: 2 November 2009

To the Editor: A recent article in the Journal describes, again, barriers to implementation of cardiometabolic monitoring among patients prescribed antipsychotic drugs.1 The cardiac health of patients with psychosis is not routinely assessed at first presentation for mental health services, adverse side effects of antipsychotic drugs are not systematically monitored, and patients with treatable risk factors for heart disease are not identified.2

  • Debra L Foley1
  • Katherine I Morley1,2
  • Karyn E Carroll1,3
  • John Moran1
  • Patrick D McGorry1
  • Brendan P Murphy4,5

  • 1 Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC.
  • 2 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, VIC.
  • 3 Melbourne Health, Melbourne, VIC.
  • 4 School of Psychology, Psychiatry and Psychological Medicine, Monash University, Melbourne, VIC.
  • 5 Recovery And Prevention of Psychosis Service, Southern Health, Melbourne, VIC.

Correspondence: dfoley@unimelb.edu.au

Acknowledgements: 

Debra Foley is supported by the Colonial Foundation, Australia. Katherine Morley is supported by a National Health and Medical Research Council (NHMRC) Post-doctoral Training Fellowship (grant no. 520452). Brendan Murphy holds a Diabetes Australia research grant.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.